# Predictive Immune Biomarkers of COVID-19 Pathogenesis to Influence Therapeutic Management

> **NCT04668170** · — · COMPLETED · sponsor: **University Hospital, Toulouse** · enrollment: 304 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Blood collection on admission and longitudinally
- **BIOLOGICAL:** Blood collection on their first consultation and 10 to 14 days later

## Key facts

- **NCT ID:** NCT04668170
- **Lead sponsor:** University Hospital, Toulouse
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-05
- **Primary completion:** 2021-12-31
- **Final completion:** 2023-05-02
- **Target enrollment:** 304 (ACTUAL)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04668170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04668170, "Predictive Immune Biomarkers of COVID-19 Pathogenesis to Influence Therapeutic Management". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04668170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*